TRIFLUPERIDOL: A BUTYROPHENONE DERIVATIVE
D. M. GALLANT M.D.,
M. P. BISHOP PH.D.,
E. TIMMONS PH.D., , and
C. A. STEELE M.D.1
1 Dept. of Psychiatry and Neurology, Tulane University School of Medicine, New Orleans, La., and East Louisiana State Hospital, Jackson, La.
Under double-blind conditions, the effects of trifluperidol, one of the butyrophenone derivatives, were contrasted with the effects of chlorpromazine in each of 2 groups of 18 chronic schizophrenics who had received no medications for at least 60 days. Trifluperidol had a significantly greater therapeutic effect than chlorpromazine not only in the global ratings of improvement but in the majority of the objective psychologic tests as well. Correlation between these clinical measurements was excellent. During the past 4 years of double-blind studies on our drug research ward, trifluperidol is the only experimental drug that has surpassed chlorpromazine in therapeutic efficacy.
